0000950170-24-038106.txt : 20240328 0000950170-24-038106.hdr.sgml : 20240328 20240328163330 ACCESSION NUMBER: 0000950170-24-038106 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240326 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Lara CENTRAL INDEX KEY: 0001769457 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 24799683 MAIL ADDRESS: STREET 1: C/O REXAHN PHARMACEUTICALS, INC. STREET 2: 15245 SHADY GROVE ROAD, SUITE 455 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 4 1 ownership.xml 4 X0508 4 2024-03-26 false 0001782223 Pyxis Oncology, Inc. PYXS 0001769457 Sullivan Lara C/O PYXIS ONCOLOGY, INC. 321 HARRISON AVENUE, 11TH FL. SUITE 1 BOSTON MA 02118 true true false false Chief Executive Officer false Stock Option (Right to Buy) 3.83 2024-03-26 4 A false 1071242 3.83 A 2034-03-26 Common Stock 1071242 1071242 D The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 26, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. /s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan 2024-03-28